• LAST PRICE
    0.0500
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0500 / 0.0500
  • Day Range
    Low 0.0500
    High 0.0500
  • 52 Week Range
    Low 0.0002
    High 0.5450
  • Volume
    327
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.05
TimeVolumeACUR
12:44 ET2200.05
02:21 ET1000.05
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesACUR
Acura Pharmaceuticals Inc
3.3M
-1.8x
---
United StatesENSC
Ensysce Biosciences Inc
2.5M
0.0x
---
United StatesOPGN
OpGen Inc
4.7M
-1.9x
---
United StatesANTI
Antigenics Inc
28.3K
0.0x
---
United StatesTCBP
TC BioPharm Ltd
4.5M
-0.3x
---
United StatesDZCA
Drazcanna Inc
1.2M
-0.2x
---
As of 2023-02-05

Company Information

Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development and commercialization of technologies and products to address safe use of medications. The Company’s platform technologies include LIMITX Technology, AVERSION Technology and IMPEDE Technology. Its LIMITX Technology is to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidate. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provides barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.

Contact Information

Headquarters
616 N North Ct Ste 120PALATINE, IL, United States 60067-8121
Phone
847-705-7709
Fax
847-705-5399

Executives

President, Chief Executive Officer, Director
Robert Jones
Chief Financial Officer, Senior Vice President, Secretary
Peter Clemens
Vice President, Corporate Controller, Treasurer
Robert Seiser
Vice President - Pharmaceutical Sciences
Albert Brzeczko
Vice President - Corporate Development
James Emigh

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.3M
Revenue (TTM)
$2.2M
Shares Outstanding
65.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.31
EPS
$-0.03
Book Value
$-0.27
P/E Ratio
-1.8x
Price/Sales (TTM)
1.4
Price/Cash Flow (TTM)
---
Operating Margin
-37.37%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.